For example, GPBAR-A-stimulated cAMP levels were lower in cells expressing hGPR17L than control-transduced cells treated with 100 nM MDL29,951, but there was no significant difference observed when treated with 100 M MDL29,951, as cAMP levels modestly increased in a concentration-dependent manner (Figure 6F)
The growing case count reflects expanding litigation involving GLP-1 receptor agonists, including similar drugs like Wegovy and Mounjaro
The only circumstances where compounding semaglutide or tirzepatide may be permissible are: True allergy to a specific inactive ingredient in the FDA-approved version, documented with allergy testing and medical records Documented medical need for a different concentration not commercially available, with clear clinical justification Specific patient population requiring dosage form modification , such as pediatric use, with proper medical justification Healthcare providers must document medical necessity with extensive clinical evidence
One study found that exenatide, a GLP-1 agonist that was approved to treat Type 2 diabetes back in 2005, significantly reduced the alcohol-cue reactivity in the area of the brain related to drug reward and addiction and significantly reduced the total alcohol intake in patients with obesity in particular
